Formulary
Cyclizine: Indications, Dosing, Side Effects and Interactions
Cyclizine clinical drug profile including indications, dosing, side effects, cautions and interactions.
MedNext Academy | 5 min read
Cyclizine: Indications, Dosing, Side Effects and Interactions
Cyclizine clinical drug profile including indications, dosing, side effects, cautions and interactions.
Indications and dose
**Nausea,Vomiting,Vertigo,Labyrinthine disorders**
- **Adult** (By Mouth, Or By Intravenous Injection, Or By Intramuscular Injection): 50 mg up to 3 times a day.
**Motion sickness**
- **Adult** (By Mouth): 50 mg up to 3 times a day, take 1-2 hours before departure.
- **Adult** (By Intravenous Injection, Or By Intramuscular Injection): 50 mg up to 3 times a day.
**Nausea and vomiting of known cause,Nausea and vomiting associated with vestibular disorders**
- **Child** (By Mouth, Or By Intravenous Injection): 12-17 years 50 mg up to 3 times a day, for motion sickness, take 1-2 hours before departure.
- **Child** (By Rectum): 12-17 years 150 mg/24 hours.
**Nausea and vomiting in palliative care**
- **Child** (By Mouth): 12-17 years 50 mg up to 3 times a day.
- **Adult** (By Mouth): 50 mg up to 3 times a day.
- **Child** (By Intravenous Injection): 12-17 years 150 mg/24 hours.
- **Child** (By Rectum): 12-17 years 50 mg up to 3 times a day.
**Nausea and vomiting of known cause, Nausea and vomiting associated with vestibular disorders for cyclizine**
- **Child 1 month-5 years** (By mouth, or by intravenous injection): 0.5-1 mg/kg up to 3 times a day (max. per dose 25 mg), for motion sickness, take 1-2 hours before departure.
- **Child 6-11 years** (By mouth, or by intravenous injection): 25 mg up to 3 times a day, for motion sickness, take 1-2 hours before departure.
- **Child 12-17 years** (By mouth, or by intravenous injection): 50 mg up to 3 times a day, for motion sickness, take 1-2 hours before departure.
- **Child 2-5 years** (By rectum): 12.5 mg up to 3 times a day.
- **Child 6-11 years** (By rectum): 25 mg up to 3 times a day.
- **Child 12-17 years** (By rectum): 50 mg up to 3 times a day.
- **Child 1-23 months** (By continuous intravenous infusion, or by continuous subcutaneous infusion): 3 mg/kg/24 hours.
- **Child 2-5 years** (By continuous intravenous infusion, or by continuous subcutaneous infusion): 50 mg/24 hours.
- **Child 6-11 years** (By continuous intravenous infusion, or by continuous subcutaneous infusion): 75 mg/24 hours.
- **Child 12-17 years** (By continuous intravenous infusion, or by continuous subcutaneous infusion): 150 mg/24 hours.
**Nausea and vomiting in palliative care for cyclizine**
- **Child 1-23 months** (By continuous subcutaneous infusion): 3 mg/kg/24 hours.
- **Child 2-5 years** (By continuous subcutaneous infusion): 50 mg/24 hours.
- **Child 6-11 years** (By continuous subcutaneous infusion): 75 mg/24 hours.
- **Child 12-17 years** (By continuous subcutaneous infusion): 150 mg/24 hours.
- **Child 1 month-5 years** (By mouth): 0.5-1 mg/kg up to 3 times a day (max. per dose 25 mg).
- **Child 6-11 years** (By mouth): 25 mg up to 3 times a day.
- **Child 12-17 years** (By mouth): 50 mg up to 3 times a day.
- **Child 1 month-5 years** (By intravenous injection): 0.5-1 mg/kg up to 3 times a day (max. per dose 25 mg).
- **Child 6-11 years** (By intravenous injection): 25 mg up to 3 times a day.
- **Child 12-17 years** (By intravenous injection): 50 mg up to 3 times a day.
- **Child 1-23 months** (By continuous intravenous infusion): 3 mg/kg/24 hours.
- **Child 2-5 years** (By continuous intravenous infusion): 50 mg/24 hours.
- **Child 6-11 years** (By continuous intravenous infusion): 75 mg/24 hours.
- **Child 12-17 years** (By continuous intravenous infusion): 150 mg/24 hours.
- **Child 2-5 years** (By rectum): 12.5 mg up to 3 times a day.
- **Child 6-11 years** (By rectum): 25 mg up to 3 times a day.
- **Child 12-17 years** (By rectum): 50 mg up to 3 times a day.
Cautions
Epilepsy; glaucoma (in children); may counteract haemodynamic benefits of opioids; neuromuscular disorders-increased risk of transient paralysis with intravenous use; prostatic hypertrophy (in adults); pyloroduodenal obstruction; severe heart failure-may cause fall in cardiac output and associated increase in heart rate, mean arterial pressure and pulmonary wedge pressure; susceptibility to angle-closure glaucoma (in adults); urinary retention
Side effects
General side-effects: Rare or very rare Agitation (more common at high doses); angle closure glaucoma; depression Frequency not known Abdominal pain; agranulocytosis; angioedema; anxiety; apnoea; appetite decreased; arrhythmias; asthenia; bronchospasm; constipation; diarrhoea; disorientation; dizziness; drowsiness; dry mouth; dry throat; euphoric mood; haemolytic anaemia; hallucinations; headache; hepatic disorders; hypertension; hypotension; increased gastric reflux; insomnia; leucopenia; movement disorders; muscle complaints; nasal dryness; nausea; oculogyric crisis; palpitations; paraesthesia; photosensitivity reaction; seizure; skin reactions; speech disorder; thrombocytopenia; tinnitus; tremor; urinary retention; vision blurred; vomiting Specific side-effects: Frequency not known With oral use Level of consciousness decreased With parenteral use Chills; consciousness impaired; injection site necrosis; pain; paralysis; sensation of pressure; thrombophlebitis
Interactions
**Other interactions (11):**
- Some phenothiazines, especially promethazine, may also increase the incidence of excitatory phenomena produced by barbiturate anaesthetics; cyclizine may possibly have a similar effect.
- Cyclizine lactate may have additive effects with alcohol and other central nervous system depressants e.g.
- Cyclizine lactate enhances the soporific effect of pethidine.
- Cyclizine lactate may counteract the haemodynamic benefits of opioid analgesics.
- Because of its anticholinergic activity, cyclizine may enhance the side-effects of other anticholinergic drugs, and may have an additive antimuscarinic action with other antimuscarinic drugs, such...
- Cyclizine lactate may mask the warning signs of damage caused by ototoxic drugs such as aminoglycoside antibacterials.
Pregnancy
Manufacturer advises avoid; however, there is no evidence of teratogenicity. The use of sedating antihistamines in the latter part of the third trimester may cause adverse effects in neonates such as irritability, paradoxical excitability, and tremor.
Breast feeding
No information available. Most antihistamines are present in breast milk in varying amounts; although not known to be harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding.
Hepatic impairment
Manufacturer advises caution.
Medicinal forms
Solution,Tablet,Solution
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Cyclizine in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary